Guanfacine is NOT Recommended for Skin-Picking Disorder
Guanfacine should not be used as a treatment for skin-picking (excoriation) disorder based on current evidence. The medication is FDA-approved only for ADHD and hypertension, and there is no guideline support or high-quality evidence demonstrating efficacy for skin-picking disorder 1.
Why Guanfacine Is Not Appropriate
Lack of Evidence Base
The available evidence consists only of:
- One single case report showing potential benefit in a patient with delusional parasitosis causing dermatillomania 2
- One retrospective cohort study in Prader-Willi Syndrome patients where 9 of 11 individuals (81.8%) showed improvement in skin-picking 3
These are extremely low-quality evidence sources that cannot support clinical recommendations for morbidity and mortality outcomes. Neither study was a controlled trial, and the Prader-Willi population represents a highly specific genetic syndrome that does not generalize to typical skin-picking disorder.
What Actually Works for Skin-Picking Disorder
According to the most recent evidence, habit reversal therapy is the first-line treatment for skin-picking disorder 4. This behavioral intervention involves:
- Awareness training to recognize picking behaviors
- Use of competing responses (e.g., making a fist rather than picking)
- Specific techniques to interrupt the habitual quality of skin-picking
When pharmacotherapy is needed, the evidence supports:
- SSRIs as first-line pharmacologic treatment - showing the most promising results in reducing severity and frequency of skin-picking symptoms 5
- N-acetyl cysteine - well-established as an effective treatment option 5
- Combination of SSRIs with psychotherapy when patients present with skin-picking disorder 5
Critical Distinction: BDD vs. Excoriation Disorder
It's essential to differentiate between:
- Skin-picking in Body Dysmorphic Disorder (BDD): Driven by attempts to improve appearance of perceived defects 4
- Excoriation (skin-picking) disorder: NOT driven by appearance concerns but rather by habitual/compulsive urges 4
This distinction matters because the underlying pathophysiology and treatment approaches differ fundamentally.
Guanfacine's Actual Indications
Guanfacine works as an alpha-2 adrenergic receptor agonist that enhances prefrontal cortex function, improving attention and impulse control 6. It is appropriately used for:
- ADHD (approved indication with medium effect sizes)
- Tic disorders/Tourette's syndrome (may reduce tics, though evidence is inconclusive) 6
- Adjunctive therapy with stimulants for ADHD 6
Significant Adverse Effects to Consider
If guanfacine were to be considered off-label, clinicians must weigh substantial adverse effects 1:
- Somnolence/sedation: 10-39% (dose-dependent)
- Dry mouth: 10-54% (dose-dependent)
- Dizziness: 2-15%
- Fatigue/asthenia: 3-10%
- Hypotension/bradycardia: Requires cardiovascular monitoring
- Constipation: 5-15%
- Dropout rates of 8-32% due to adverse effects in clinical trials
These risks are unacceptable without evidence of benefit for the target condition.
Clinical Bottom Line
Use evidence-based treatments for skin-picking disorder: Start with habit reversal therapy, and if pharmacotherapy is needed, use SSRIs or N-acetyl cysteine 4, 5. The two case reports suggesting guanfacine benefit 2, 3 are insufficient to justify its use given the availability of proven alternatives and the medication's significant adverse effect profile.
If a patient has comorbid ADHD and skin-picking disorder, guanfacine may be appropriate for the ADHD component, but do not expect it to treat the skin-picking behavior based on current evidence.